With no evidence to support the claim that 10 children died due to COVID-19 vaccines, experts unpack the impact of CBER chief ...

While Imvax’s autologous immunotherapy IGV-001 missed the primary endpoint of progression-free survival in a Phase IIb trial, ...

This week's meeting of the Advisory Committee on Immunization Practices will be led by Kirk Milhoan, a physician and pastor ...

More than nine in 10 patients treated with Roche’s next-generation Alzheimer’s disease antibody trontinemab tested negative ...

Agentic AI can help FDA staff manage meetings, conduct pre-market reviews and validate reports, among other tasks, though the ...

After covering the Alzheimer’s space through every high and low, BioSpace’s Annalee Armstrong welcomes back Roche for the 2026 Alzheimer’s Renaissance.

Following FDA rejections, Regeneron and Scholar Rock are turning to other facilities to clear regulatory logjams created by ...

The U.K.’s National Health Service will increase the net price paid for new medicines by 25% under the agreement. The nation ...

Following Novo Nordisk’s price cuts for its own GLP-1 medicines, Eli Lilly is offering discounts for the obesity drug ...

Protego Biopharma is advancing a small-molecule drug that helps light chain proteins fold correctly, in turn addressing the ...

If approved, Ascendis’ TransCon CNP would become the second therapy for achondroplasia, challenging BioMarin’s Voxzogo.

As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, ...